Daxor Corporation Common Stock (DXR)
Stock · NASDAQ · Health Care
$10.05as of 10/16/2026
Price chart
Active signals
DXR Signal Track Record
How signals performed across all stocks →What DXR's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Bollinger Band Breakdown | 25 | +0.4% | 56% | August 21, 2026 |
| Bollinger Band Breakout | 22 | -3.4% | 32% | September 16, 2026 |
| 200-Day Moving Average TouchActive now | 20 | -1.6% | 40% | September 14, 2026 |
| Volume Spike | 6 | -9.0% | 0% | September 11, 2026 |
| Any 20-session window (baseline) | -0.5% | 46% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About DXR
Daxor Corporation engages in medical instrumentation and biotechnology operations. It develops the BVA-100 Blood Volume Analyzer, an instrument that measures human blood volume, in conjunction with Volumex, a single-use radiopharmaceutical diagnostic injection and collection kit. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporat…
- Sector
- Health Care
- Industry
- Medical/Dental Instruments
- Website
- www.daxor.com/
Fundamentals
- 1-day range
- $10.08$10.36
- Market cap
- $61.18M
- P/E (trailing)
- 10.12
- P/E (forward)
- —
- EPS (trailing)
- $1.52
- Dividend yield
- —
- Beta
- 0.38
- Avg. volume
- 17.9K
- Ex-dividend date
- January 5, 2018
- Dividend pay date
- January 12, 2018
Forecasts
2 analyst ratings
Daxor Corporation Common Stock Competitors
Chosen by industry and closest market cap.
- DXRDaxor Corporation Common Stock$10.05▼ 1.47%Market cap $61.18MP/E 10.12$8.56$14.76
- XTNTXtant Medical Holdings Inc. Common Stock$0.29▼ 3.33%Market cap $62.09MP/E 23.84$0.2702$0.95
- QTEXQTREX Quantum Ltd. Ordinary Shares$1.5▼ 5.06%Market cap $59.05MP/E —$0.283$3.85
- NYXHNyxoah SA Ordinary Shares$1.11▼ 6.72%Market cap $57.20MP/E —$1.11$5.3
- DRIODarioHealth Corp. Common Stock$4.82▼ 6.04%Market cap $56.88MP/E —$5.03$16.5
- MDAISpectral AI Inc. Class A Common Stock$1.51▼ 1.95%Market cap $52.83MP/E —$1.18$2.97
- LNSRLENSAR Inc. Common Stock$5.8▼ 3.81%Market cap $70.43MP/E 2.15$4.95$12.94
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| DXR Daxor Corporation Common Stock | $61.18M | 10.12 | $10.05 | ▼ 1.47% | $8.56$14.76 |
| XTNT Xtant Medical Holdings Inc. Common Stock | $62.09M | 23.84 | $0.29 | ▼ 3.33% | $0.2702$0.95 |
| QTEX QTREX Quantum Ltd. Ordinary Shares | $59.05M | — | $1.5 | ▼ 5.06% | $0.283$3.85 |
| NYXH Nyxoah SA Ordinary Shares | $57.20M | — | $1.11 | ▼ 6.72% | $1.11$5.3 |
| DRIO DarioHealth Corp. Common Stock | $56.88M | — | $4.82 | ▼ 6.04% | $5.03$16.5 |
| MDAI Spectral AI Inc. Class A Common Stock | $52.83M | — | $1.51 | ▼ 1.95% | $1.18$2.97 |
| LNSR LENSAR Inc. Common Stock | $70.43M | 2.15 | $5.8 | ▼ 3.81% | $4.95$12.94 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
Insider Activity
Insider Actions →- John Jefferies · August 28, 2026 · Grant2.5K
- DesRosiers Caleb · June 23, 2026 · Grant2.5K
- Goudie Joy S. · June 23, 2026 · Grant2.5K
- Cremisi Henry D. · June 23, 2026 · Grant2.5K
- Jonathan Adam Feldschuh · June 23, 2026 · Grant25.0K
- Edward Feuer · June 23, 2026 · Grant2.5K
- Michael Richard Feldschuh · June 23, 2026 · Grant30.0K
- Robert J. Michel · June 23, 2026 · Grant12.0K
Institutional Ownership
March 31, 2026
- Total shares held
- 419.1K
- Total value held
- $1.81M
- Institutional holders
- 13
- Unknown232.1K
- Unknown48.3K
- Unknown41.7K
- Unknown28.0K
- Unknown25.2K
- Unknown13.7K
- Unknown12.5K
- Unknown10.7K
- Unknown3.1K
- Unknown3.1K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 2, 2026
Daxor to Present New Blood Volume Analyzer and Data at HFSA 2026
Daxor Corporation announced it will showcase its next-generation blood volume analyzer and share new clinical data at the HFSA 2026 conference. This presentation highlights the company's focus on advancing its medical technology offerings. The stock is currently trading near its 200-day moving average, with an average analyst target of $20.00.
Daxor to Present New Blood Volume Analyzer and Data at HFSA 2026. Daxor Corporation announced it will showcase its next-generation blood volume analyzer and share new clinical data at the HFSA 2026 conference. This presentation highlights the company's focus on advancing its medical technology offerings. The stock is currently trading near its 200-day moving average, with an average analyst target of $20.00.